This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Coles, A J Articles by Compston, D A. Search for Related Content PubMed PubMed Citation Articles by Coles, A J Articles by Compston, D A. Pubmed/NCBI databases Medline Plus Health Information Multiple Sclerosis Social Bookmarking                   What's this?

Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy

University of Cambridge Neurology unit, Box 165, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ

M G Wing

University of Cambridge Neurology unit, Box 165, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ

D AS Compston

MRC Cambridge Centre for Brain Repair, University Forvie Site, Robinson Way, Cambridge CB2 2PY, UK

There is no established immunological marker of multiple sclerosis activity, which reflects the poor understanding of the immunopathogenesis of multiple sclerosis. Passive measurement of the levels of soluble inflammatory markers, whose half lives are usually measured in minutes and hours, can only indicate the extent of instantaneous inflammation, which is known to fluctuate in multiple sclerosis. We favour measurement of immune responses in vitro. As healthy individuals have T cell reactivities to myelin proteins that are postulated to be pathogenic in multiple sclerosis,^1,2 we prefer non-antigen specific mitogen and recall antigen assays as immunological markers. We illustrate their use in the treatment of 27 patients with multiple sclerosis using a pulse of humanised anti-lymphocyte (CD52) antibody that caused prolonged T cell depletion. The mitogen-induced proliferation, and secretion of IFN-g, from peripheral blood mononuclear cells in vitro was significantly reduced after treatment, suggesting that immune responses had been modulated. Such observations will only gain credence as an outcome measure if they are shown to correlate with clinical or radiological measures of multiple sclerosis activity. Perhaps more importantly, aspects of the pathogenesis of multiple sclerosis may be revealed by close immunological surveillance of patients undergoing experimental treatments.

Key Words: Campath-1H • multiple sclerosis • T-helper 1 • T-helper 2 • peripheral blood mononuclear cells • Graves' • autoimmune thyroiditis

Multiple Sclerosis, Vol. 4, No. 3, 232-238 (1998)
DOI: 10.1177/135245859800400327


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?